gfh925
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 10, 2021 (NCT05005234)
Timeline
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07198841 | Phase 2 | Sep 30, 2025 | Guangdong Association of Clinical Trials, Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06959589 | Phase 2 | Jun 1, 2025 | Zhejiang University |
| NCT05756153 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2023 | Zhejiang Genfleet Therapeutics Co., Ltd. |
| NCT05699993 | Phase 1 | Mar 10, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05688124 | Phase 1 | Feb 16, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05626179 | Phase 1 | Dec 16, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05504278 | Phase 1 | Aug 31, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05497336 | Phase 1 | Aug 18, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05005234 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2021 | Zhejiang Genfleet Therapeutics Co., Ltd. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 6 | 5 | 2 | 2022 |
| Zhejiang Genfleet Therapeutics Co., Ltd. | For profit | 2 | 2 | 1 | 2021 |
| Guangdong Association of Clinical Trials | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1